Viruses Mutate, But Treatments Are Static. Is There a Way to Change That?

There is a big, global problem: viruses such as HIV and COVID-19 mutate, but treatments for them don’t.

Experts Discuss How Science Will Drive COVID-19 Recovery

UCSF gathered leading Bay Area scientists and clinicians to reflect on the scientific challenges and breakthroughs of the past year since COVID-19 was declared a pandemic.

New Study Will Examine How Robustly Individuals Respond to COVID-19 Vaccination

This will be one of the first and largest studies to examine the impact of factors like age and stress on vaccination effectiveness.

COVID-19 Study Finds Increase of Coronavirus Variants in San Francisco’s Mission District 

New results from an ongoing collaborative effort to slow the spread of COVID-19 shows that the prevalence of a coronavirus lineage, characterized by the L452R substitution and two other mutations in the virus’s spike protein, has significantly increased in recent months.

Study Estimates Excess Deaths in US from COVID-19 Pandemic Unemployment 

UCSF researchers now have an estimate of how many people may have died as a result of pandemic-related unemployment.

UCSF Partnership With San Francisco Brings COVID-19 Vaccinations to the Mission District

The vaccination site builds off previous work with Unidos en Salud to bring COVID-19 testing to the Mission District.

UCSF Expands Vaccination Effort in Partnership with City of San Francisco

As its supply of COVID-19 vaccines increases, UC San Francisco is expanding its vaccination efforts to those most at risk – the elderly and health care workers in the community

COVID-19 Vaccine Fact Vs. Fiction: An Expert Weighs in on Common Fears

We posed the most common COVID-19 vaccine quandaries to Bryn Boslett, MD, an infectious disease expert who is leading the vaccination effort at UCSF. She explains why mRNA vaccines won’t affect your DNA, which allergies pose a risk, what 95 percent efficacy really means, and more.

Severe COVID-19 Disables Disease-Fighting Immune Circuit 

Patients with severe COVID-19 produce antibodies that paradoxically shut down their immune system’s virus-fighting response just when they need it most.

Cancer Drug Shows Potent Activity in the Lab Against SARS-CoV-2, Including New Variants

In two preclinical models of COVID-19, plitidepsin showed a 100-fold reduction in viral replication in the lungs and demonstrated an ability to reduce lung inflammation.